stockmando
Posted - 12 hours ago
$IFRX it's your time, Jan Medina!
otcgtc
Posted - 16 hours ago
$IFRX ...InflaRx will participate in a panel titled, New Potential Dermatology Treatments for Psoriasis, Urticaria, and Alopecia scheduled on May 14, 2024, at 2:30 PM EDT / 8:30 PM CEST... buzz word is Alopecia !!
Stock_Titan
Posted - 18 hours ago
$IFRX InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
https://www.stocktitan.net/news/IFRX/infla-rx-to-participate-in-capital-one-securities-1st-annual-biotech-cxmtdaip3nrt.html
levystrauss
Posted - 21 hours ago
$IFRX I wrote 4 years for phase 3 ARDS still not started and its approval, I was wrong it will probably take 5 years. 2-3 years for the definitive data, 1-1.5 years for the approval request and 6 months to prepare for marketing, in the meantime they will have required at least 2-3 OFFERINGS and dilutions. A miracle would be needed here
levystrauss
Posted - 21 hours ago
$IFRX I wonder what the CEO is doing these months. He didn't sell anything from Gohibic, he didn't provide any news on agreements, nothing seems like in Jena they are playing cards with each other and then every now and then some trips and conferences on sepsis
levystrauss
Posted - 21 hours ago
$IFRX There is a phase 3 that hasn't started yet (they don't have enough money) and if it ever starts it will take at least 4 years to obtain approval and then market the product, and other pharmaceutical companies will already be on the market. The only solution is to sell this company to Pfizer or JJ, otherwise we will be diluted until 2030, how sad to have a CEO like this
levystrauss
Posted - 21 hours ago
$IFRX always red here, nothing new. By now we are used to seeing IFRX shares collapse. A rise to 2 dollars is difficult, in fact it will be easier to fall to 0.50 in the coming months. But I'd be happy to be wrong. Only in 2025 will we perhaps have some positive data, many here will no longer be here, Mister Compassion will continue to pump and talk about sepsis which in reality has no relation to IFRX for now. In fact, they have no pipeline on sepsis
Jrzo
Posted - 1 day ago
$IFRX - just received " voting instruction" for vote on 9 items , most of which I am against , especially releasing directors from liability from their performance , never mind re appointing them, and also voting for further dilution of equity. Vote had to be in by April 21st to count, I received notification of this April 23rd. When i logged in, it looks like my votes were voted for me, of course all FOR the proposals set forth. This is not my area of expertise but seems a tad bit wrong...no ?
JerzeyDevil
Posted - 1 day ago
$IFRX lol
stockmando
Posted - 1 day ago
$IFRX Was just reading comments on SA about IFRX back in 2018-19 years when stock was at $36, and man, there is so many people were wrong and lost a lot of $.... Many folks compared CCXI with IFRX and were right. They choose CCXI over IFRX. Some people bet on IFRX. Will be great to hear their opinion now, 6 years later. But of course, many investors just moved on.
TheWinningStock
Posted - 1 day ago
$AKBA <<<--- market cap should be north of $10b>. $IFRX $CRDL Anktiva provides enough efficacy to help with other types of cancers.
MrCompassion
Posted - 1 day ago
$IFRX https://wscspotlight.org/ Today, starting at 09:00h CEST: World Sepsis Congress Spotlight: Unmet Need in Sepsis Diagnosis and Therapy Noted Speakers: Dr. Giamarellos-Bourboulis, who was the principal investigator of the InflaRx HS p2 study, will be presenting: Biomarkers as Endpoints for Treatment Efficacy (session 5 which begins at 14:30h CEST) Dr. Alexander Vlaar, who was the principal investigator of the InflaRx panamo study leading to EUA of Vilo in care of viral sepsis, will be presenting: Modulation of Complement (session 8 which begins at 19:00h CEST) Also maybe of interest: Dr. Lena Napolitano, out of U. of Michigan, will be presenting: Research Priorities for Sepsis and Septic Shock in Surgical Patients (session 2 which begins at 10:00h CEST) - as described in the following article, used a SeaStar Medical device which “selectively targets the most highly activated pro-inflammatory neutrophils and monocytes” in treatment of a severe covid patient https://www.michiganmedicine.org/health-lab/meet-man-who-spent-75-days-hospital-covid-19
Dave1961
Posted - 2 days ago
$IFRX Keep loading up folks. This is a golden opportunity to average down on your average PPS if you have been holding this for a while. The drug is best in class and you should take advantage of the discounted price right now. You will certainly thank yourself later. Good things come to those who wait. Many of us have been here holding a few years. It’s starting to feel like it may be turning around for us all. 🤞
stockmando
Posted - 2 days ago
$IFRX May 9 is earning report? Is it confirmed?
Avorio
Posted - 2 days ago
$IFRX Nice bid 💪 C'mon.
PaulieWalnutsAlwaysWins
Posted - 2 days ago
$IFRX how's my favorite piece of shit in the whole market?
mconnell
Posted - 2 days ago
$IFRX 2024-04-22 13F Raymond James & Associates 242,620 38.42 % increase 2024-04-22 13F Raymond James Financial Services Advisors, Inc. 384,972 21.11 % increase! HOld
hrkvgkv
Posted - 2 days ago
$IFRX At present, I have two questions: 1. After GOHIBIC made its commitment in January, will there be an increase in sales? If so, and if the sales are obvious, will the data be submitted to MAA as a European launch? in accordance with. 2. PG will be the first to join the group in November 2023. Will it make a very good evaluation in the first quarter? If the effect is good, I think we are likely to enter the stock upward channel.
MrCompassion
Posted - 2 days ago
$IFRX At current price, it’s about as certain as it gets that one can make 50x to 100x on their money, invested in IFRX. As such, you can afford to buy this guy a beer, while discussing your favorite topic: the role of neutrophils in immune function. Here is Dr. Arturo Zychlinsky https://twitter.com/zychlinsky, who led the research team that discovered Neutrophil Extracellular Traps (NETs) in 2004. 100 billion neutrophils released into the bloodstream each day. 200 thousand C5a receptors per neutrophil. C5a-C5aR binding, leading to signaling of neutrophils to the site of pathogenic threat (chemotaxis). Formation of NETs as part of the mechanism to neutralize pathogens, that in excess – too much C5a-C5aR signaling – will damage nearby otherwise healthy tissue in the process. Control this signaling, control neutrophil concentration, control NET formation, control organ damage. That’s it in a nutshell: 50x to 100x because of that science. Thank you InflaRx, and thank you Dr. Zychlinsky!
rusi1
Posted - 2 days ago
$IFRX someone expects good news on April 25?
FlowerInTheCellar
Posted - 2 days ago
$IFRX https://www.inflarx.de/Home/Investors/Annual-Extraordinary-General-Meetings.html April 25, 2024: Annual General Meeting of Shareholders of InflaRx N.V. The annual general meeting of shareholders of InflaRx N.V. (the "Company") will be held on April 25, 2024 at 09:00 a.m. Amsterdam time (CEST) at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the "AGM"). Convening notice incl. agenda and explanatory notes - 2024 AGM InflaRx NV Voting Proxy AGM 2024 Deed of amendment Articles InflaRx N.V. (ENG version) Deed of Amendment InflaRx N.V. (NL version) InflaRx N.V. Dutch Board Report 2023 InflaRx N.V. EY Auditor Report 2023
morgueana
Posted - 4 days ago
$IFRX My Schwab account has next quarterly reporting on May 9th. The double-blind PG study is reaching a point where it may be fully enrolled. There are readouts of response being done after several weeks on Vilo (blind to the Ifrx team). If patients fail, they are counted against the final tally and removed from the study, and if enough fail, at this juncture the study would be halted by the independent party which was set up with FDA approval to conserve infx resources. The number of enrollees will be between 50 and 100 which is arguably small and I believe reflects confidence in the results. The longer we do not hear of a halt the greater the chances of a significant p value. Last CC Niels commented that "we may already be fully enrolled". The fewer subjects that need to be enrolled means the study is going stellar. The final data sets will be read out next year and then Vilo can be submitted for FDA approval if all goes well.
morgueana
Posted - 4 days ago
$IFRX Another issue that Niels addressed last CC was the reason that the HS trial failed in Vilo vs placebo. He said that the Pharmakinetics of the drug is such that is reaches peak serum levels very rapidly and the drug dosing did not take this into account which they now feel that steady state levels are necessary for an HS response. The dosing interval needs to be stepped up. So in steps inf 904 with its 10 fold higher serum concentrations with dosing than Avacopan and they can give it more often ORALLY and at a higher dose with safety to titrate the HS response just right. Exciting times ahead. Will we hear of a start date in both urticaria and hidrenitis on the upcoming CC?
morgueana
Posted - 4 days ago
$IFRX My Schwab account has next quarterly reporting on May 9th. The double-blind PG study is reaching a point where it may be fully enrolled. There are readouts of response being done after several weeks on Vilo (blind to the IFRX team). If patients fail they are counted against the final tally and removed from the study and if enough fail at this juncture the study could be halted by the independent party. The number of enrollees will be between 50 to 100 which is arguably small, and I believe reflects confidence on the part of IFRX scientists. The longer that we do not hear of a halt because of poor data, the greater the chances we will reach a statistical p value. Last cc Niels commented that "we may be already fully enrolled". The data set final read out is not planned until 2025 but the longer this study goes on the more likely we are going to see an FDA approval as early as next year. The fewer subjects that need to be enrolled means the study is going stellar.
stockmando
Posted - 5 days ago
$IFRX There is still active CALLs with 2.50 strike. Maybe thats why its up?
mconnell
Posted - 5 days ago
$IFRX This looks like a rock start compared to the rest of the market.
Noble98
Posted - 5 days ago
$IFRX Wouldn’t want to go into the weekend without shares. 😉
stockmando
Posted - 5 days ago
$IFRX If $LABU get some relieve rally, IFRX will follow.